%0 Journal Article
%T Targeted Cancer Therapy-on-A-Chip.
%A Abed H
%A Radha R
%A Anjum S
%A Paul V
%A AlSawaftah N
%A Pitt WG
%A Ashammakhi N
%A Husseini GA
%J Adv Healthc Mater
%V 0
%N 0
%D 2024 Aug 5
%M 39101627
%F 11.092
%R 10.1002/adhm.202400833
%X Targeted cancer therapy (TCT) is gaining increased interest because it reduces the risks of adverse side effects by specifically treating tumor cells. TCT testing has traditionally been performed using two-dimensional (2D) cell culture and animal studies. Organ-on-a-chip (OoC) platforms have been developed to recapitulate cancer in vitro, as cancer-on-a-chip (CoC), and used for chemotherapeutics development and testing. This review explores the use of CoCs to both develop and test TCTs, with a focus on three main aspects, the use of CoCs to identify target biomarkers for TCT development, the use of CoCs to test free, un-encapsulated TCTs, and the use of CoCs to test encapsulated TCTs. Despite current challenges such as system scaling, and testing externally triggered TCTs, TCToC shows a promising future to serve as a supportive, pre-clinical platform to expedite TCT development and bench-to-bedside translation.